# US 2023/0265166 A1 · Young and undamaged human serum albumin improves longevity of human

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265166 A1
- Document ID: US20230265166A1
- Status: Published application
- Kind: A1
- Application number: 18/041,319
- Filed: 2021-08-11
- Published: 2023-08-24
- Earliest claimed: 2020-08-11
- Applicants: Shenzhen Protgen Ltd.
- Inventors: Yongzhang Luo; Yan FU; Jiaze TANG; Anji JU; Boya LI; Yuanchao GONG; Shaosen ZHANG; Guodong CHANG; Hui LI
- Web page: https://patentgrep.com/patent/US20230265166A1

## CPC

- C07K 14/765: Serum albumin, e.g. HSA
- A61K 38/385: {Serum albumin}
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/765: Serum albumin, e.g. HSA
- G01N 2440/00: Post-translational modifications [PTMs] in chemical analysis of biological material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided is a method of extending lifespan and/or anti-aging in a subject, comprising the step of administering to the subject an effective amount of a preparation of young and undamaged human serum albumin (HSA), wherein the preparation exhibits at least one, preferably all, of the following properties: (1) higher ratio of free thiol in Cys-34 residue, (2) lower level of advanced glycation end-product (AGE), (3) lower level of carbonylation, and (4) lower level of homocysteinylation, as compared to an endogenous HSA preparation obtained from said subject.

## Claims

### Claim at position 1

1: A preparation of young and undamaged human serum albumin (HSA) that exhibits at least one or all of the following properties: (1) higher ratio of free thiol in Cys-34 residue, (2) lower level of advanced glycation end-product (AGE), (3) lower level of carbonylation, and (4) lower level of homocysteinylation, as compared to an endogenous HSA preparation obtained from a young individual of human.

### Claim at position 2 (depends on 1)

2: The preparation of claim 1, wherein the young individual is below age of 30.

### Claim at position 3 (depends on 1)

3: The preparation of claim 1, wherein the preparation exhibits at least one or all of the following properties: (1) the ratio of free thiol in Cys-34 residue being greater than 50%, as determined by the Ellman's method; (2) the level of advanced glycation end-product (AGE) being lower than 60 μg/g protein, as determined by ELISA (CLOUD-CLONE Co., CEB353Ge); (3) the level of carbonyl is lower than 1.7 nmol/mg protein, as determined by Protein Carbonyl Content Assay Kit (Abcam); and (4) the level of homocysteine is lower than 5 nmol/g protein as determined by ELISA (Jianglai, JL10022).

### Claim at position 4 (depends on 1)

4: The preparation of claim 1, wherein the ratio of free thiol in Cys-34 residue is greater than 80%.

### Claim at position 5 (depends on 1)

5: The preparation of claim 1, wherein the level of AGE is lower than 30 μg/g protein.

### Claim at position 6 (depends on 1)

6: The preparation of claim 1, wherein the level of carbonyl is lower than 1.5 nmol/mg protein.

### Claim at position 7 (depends on 1)

7: The preparation of claim 1, wherein the level of homocysteine is lower than 2 nmol/g protein.

### Claim at position 8 (depends on 1)

8: The preparation of claim 1, wherein the ratio of free thiol in Cys-34 residue is greater than 80%, the level of AGE is lower than 30 μg/g protein, the level of carbonyl is lower than 1.5 nmol/mg protein, the level of homocysteine is lower than 2 nmol/g protein.

### Claim at position 9 (depends on 1)

9: The preparation of claim 1, wherein the preparation is produced recombinantly or purified from plasma.

### Claim at position 10

10-17. (canceled)

### Claim at position 11

18: A method of extending lifespan and/or anti-aging in a subject, comprising the step of administering to the subject an effective amount of a preparation of young and undamaged human serum albumin (HSA), wherein the preparation exhibits at least one or all of the following properties: (1) higher ratio of free thiol in Cys-34 residue, (2) lower level of advanced glycation end-product (AGE), (3) lower level of carbonylation, and (4) lower level of homocysteinylation, as compared to an endogenous HSA preparation obtained from said subject.

### Claim at position 12 (depends on 18)

19: The method of claim 18, wherein the preparation exhibits at least one or all of the following properties: (1) the ratio of free thiol in Cys-34 residue being greater than 50%, as determined by the Ellman's method; (2) the level of advanced glycation end-product (AGE) being lower than 60 μg/g protein, as determined by ELISA (CLOUD-CLONE Co., CEB353Ge); (3) the level of carbonyl is lower than 1.7 nmol/mg protein, as determined by Protein Carbonyl Content Assay Kit (Abeam); and (4) the level of homocysteine is lower than 5 nmol/g protein, as determined by ELISA (Jianglai, JL10022).

### Claim at position 13 (depends on 18)

20: The method of claim 18, wherein the ratio of free thiol in Cys-34 residue is greater than 80%.

### Claim at position 14 (depends on 18)

21: The method of claim 18, wherein the level of AGE is lower than 30 μg/g protein.

### Claim at position 15 (depends on 18)

22: The method of claim 18, wherein the level of carbonyl is lower than 1.5 nmol/mg protein.

### Claim at position 16 (depends on 18)

23: The method of claim 18, wherein the level of homocysteine is lower than 2 nmol/g protein, as determined by ELISA.

### Claim at position 17 (depends on 18)

24: The method of claim 18, wherein the ratio of free thiol in Cys-34 residue is greater than 80%, the level of AGE is lower than 30 μg/g protein, the level of carbonyl is lower than 1.5 nmol/mg protein, the level of homocysteine is lower than 2 nmol/g protein.

### Claim at position 18 (depends on 18)

25: The method of claim 18, wherein the subject is a patient or a healthy individual.

### Claim at position 19 (depends on 1)

26: A pharmaceutical composition, comprising the preparation of young and undamaged human serum albumin as defined in claim 1 and a pharmaceutically acceptable carrier.

### Claim at position 20

27: A method for monitoring the change of aging status of a subject, comprising:
obtaining a sample of human serum albumin (HSA) from the subject;
testing in the sample at least one or all of the following four parameters of HSA: (1) ratio of free thiol in Cys-34 residue, (2) level of advanced glycation end-product (AGE), (3) level of carbonylation, and (4) level of homocysteinylation;
if the ratio of free thiol in Cys-34 residue increases and/or the level of AGE, the level of carbonylation and/or the level of homocysteinylation decreases, as compared to the data from an earlier test from the same subject, it is determined that the aging status of the subject is improved.

### Claim at position 21 (depends on 1)

28: A method of improving the function of skeletal muscle and/or improving the cognitive ability in a subject, comprising the step of administering to the subject an effective amount of a preparation of young and undamaged human serum albumin (HSA) as defined in claim 1.